Serum Metabolomic Profiling Correlated with ISS and Clinical Outcome for Multiple Myeloma Patients Treated with High-dose Melphalan and Autologous Stem Cell Transplantation.

[1]  Katarzyna A. Broniowska,et al.  Metabolomic and Lipidomic Profiling of Bone Marrow Plasma Differentiates Patients with Monoclonal Gammopathy of Undetermined Significance from Multiple Myeloma , 2020, Scientific Reports.

[2]  Leslie R Euceda,et al.  Assessing treatment response and prognosis by serum and tissue metabolomics in breast cancer patients. , 2019, Journal of proteome research.

[3]  J. Yi,et al.  Apolipoproteins and cancer , 2019, Cancer medicine.

[4]  E. Drakos,et al.  Apolipoprotein A-I (ApoA-I), Immunity, Inflammation and Cancer , 2019, Cancers.

[5]  Krista A. Zanetti,et al.  Pre-Analytical Factors that Affect Metabolite Stability in Human Urine, Plasma, and Serum: A Review , 2019, Metabolites.

[6]  P. Liu,et al.  Identification of High Serum Apolipoprotein A1 as a Favorable Prognostic Indicator in Patients with Multiple Myeloma , 2019, Journal of Cancer.

[7]  Yi Zhang,et al.  Prognostic Significance of Pretreatment Apolipoprotein A-I as a Noninvasive Biomarker in Cancer Survivors: A Meta-Analysis , 2018, Disease markers.

[8]  I. Turesson,et al.  Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival , 2018, European journal of haematology.

[9]  U. Mellqvist,et al.  Outcome and survival of myeloma patients diagnosed 2008–2015. Real-world data on 4904 patients from the Swedish Myeloma Registry , 2017, Haematologica.

[10]  Olle Melander,et al.  Apolipoproteins, lipids and risk of cancer , 2016, International journal of cancer.

[11]  M. Sarfaraz,et al.  Temporal characterization of serum metabolite signatures in lung cancer patients undergoing treatment , 2016, Metabolomics.

[12]  Rui Pinto,et al.  Serum nuclear magnetic resonance-based metabolomics and outcome in diffuse large B-cell lymphoma patients – a pilot study , 2016, Leukemia & lymphoma.

[13]  S. Rajkumar.  Myeloma today: Disease definitions and treatment advances , 2016, American journal of hematology.

[14]  Qingtao Wang,et al.  Proteomic Analysis for Finding Serum Pathogenic Factors and Potential Biomarkers in Multiple Myeloma , 2015, Chinese medical journal.

[15]  H. Goldschmidt,et al.  Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Simone Wahl,et al.  Targeted Metabolomics Identifies Reliable and Stable Metabolites in Human Serum and Plasma Samples , 2014, PloS one.

[17]  E. Jobard,et al.  A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer. , 2014, Cancer letters.

[18]  S. Vincent Rajkumar,et al.  Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients , 2013, Leukemia.

[19]  Stanley L Hazen,et al.  The Cardioprotective Protein Apolipoprotein A1 Promotes Potent Anti-tumorigenic Effects*♦ , 2013, The Journal of Biological Chemistry.

[20]  G. Morgan,et al.  Proton NMR-Based Metabolite Analyses of Archived Serial Paired Serum and Urine Samples from Myeloma Patients at Different Stages of Disease Activity Identifies Acetylcarnitine as a Novel Marker of Active Disease , 2013, PloS one.

[21]  A. Dirican,et al.  Stability studies of common biochemical analytes in serum separator tubes with or without gel barrier subjected to various storage conditions , 2012, Biochemia medica.

[22]  Ivano Bertini,et al.  Metabolomic NMR fingerprinting to identify and predict survival of patients with metastatic colorectal cancer. , 2012, Cancer research.

[23]  S. Sleijfer,et al.  Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  R A Kyle,et al.  Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma , 2009, Leukemia.

[25]  M. Drayson,et al.  Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. , 2006, Blood.

[26]  J. Crowley,et al.  International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R. Collins,et al.  Stability of plasma analytes after delayed separation of whole blood: implications for epidemiological studies. , 2003, International journal of epidemiology.

[28]  G. Favre,et al.  Quantitative Abnormalities of Lipoprotein Particles in Multiple Myeloma , 1987, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.